Comparative Safety of Seizure Prophylaxis within the Medicare Program
医疗保险计划中癫痫预防的比较安全性
基本信息
- 批准号:10495203
- 负责人:
- 金额:$ 82.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-30 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AcademyAcuteAddressAdverse effectsAdverse eventAdvisory CommitteesAlzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAmericanAmerican Heart AssociationAnticonvulsantsCase SeriesCenters for Disease Control and Prevention (U.S.)ClinicalClinical ManagementClinical TrialsCommunitiesComplexComplicationCox Proportional Hazards ModelsDataData SetDetectionDiagnosisDrug LabelingDrug usageElderlyElectroencephalographyElectronic Health RecordEmergency department visitEnrollmentEpilepsyEtiologyEventFamilyFee-for-Service PlansFoundationsFutureGuidelinesHospitalizationIncentivesIndividualIschemic StrokeLifeLinkLiteratureMeasuresMedicareMedicare Part AMedicare claimMethodsModelingNamesNational Committee for Quality AssuranceNeurologyObservational StudyOutcomeOutpatientsPatient CarePatientsPatternPharmaceutical PreparationsPhysiciansPoliciesPolicy MakerPositioning AttributePredispositionProphylactic treatmentProviderRegistriesRelative RisksRiskSafetySamplingSavingsScoring MethodSeizuresSerious Adverse EventSeveritiesStrokeSymptomsTherapeuticTimeValidationacute strokeadjudicateadverse event riskagedanalytical toolbasebeneficiaryclinical carecomorbiditycomparative safetycostdementia careelectronic dataexperiencefall injuryfallsfollow-uphigh riskimprovedindividualized medicinemachine learning methodmultidisciplinarynovelpopulation basedpost strokepredictive modelingpreventprogramsrandomized trialrecruitsafety studystroke eventstroke riskstroke survivortreatment durationtrial comparing
项目摘要
PI Name(s): Moura, Lidia Maria Veras Rocha de
Project Title: Comparative Safety of Seizure Prophylaxis within the Medicare Program
1R01AG073410-01
Each year thousands of Medicare beneficiaries with Alzheimer’s disease and/or Alzheimer’s-related dementias (AD/ADRD) receive anticonvulsant drugs for seizure prophylaxis. These drugs are life-saving given the severity of seizure sequalae, but also life-threatening because of serious adverse events. Patients with AD/ADRD are particularly vulnerable given their high susceptibility to both stroke and adverse events. The decision to start and stop anticonvulsants also might change when the patient have AD/ADRD, in part because anticonvulsant therapy management becomes more complex when patients have difficulty with therapy having a narrow therapeutic range or difficulty recognizing early complication symptoms. There are no trial data to guide decisions about prophylaxis after an ischemic stroke among patients with or without AD/ADRD. The sparse and conflicted existing literature has been limited by the difficulty assessing relevant measures, e.g., stroke severity or AD/ADRD status, in claims. Medicare claims offer potential, but lack well-validated definitions for stroke severity, AD/ADRD status, seizures, or adverse effects. We will address these issues using a novel dataset with individual-level linked longitudinal information from registries, electronic health records, and Medicare claims, and will develop prediction models for key baseline and outcome variables. Then, using a random 20% sample of national traditional, fee-for-service Medicare claims over 18 years (2006-23), we will emulate clinical trials assessing two critical decisions in the setting of first mild to moderate ischemic stroke among patients with or without AD/ADRD: a) initiating outpatient prophylaxis versus not; and b) stopping prophylaxis at six months versus continuing. We will apply multiple analytical tools to address confounding and other challenges. We will stratify our population based on AD/ADRD status because the patterns of strokes, post-stroke seizures, and treatment complications differ among patients with compared to those without AD/ADRD, as could the clinical management patterns. We have three aims: 1) To validate claims-based prediction models for our study variables; 2) To emulate a clinical trial comparing outpatient prophylaxis initiation versus not; and 3) To emulate a clinical trial comparing stopping outpatient prophylaxis at six months versus continuing. This comparative safety study could inform future policy and clinical care and improve stroke and AD/ADRD care, e.g., through adjustments in Medicare quality incentives and clinical guidelines. Moreover, these data could help inform patients, families, clinicians, and policy makers about how we can improve care for patients who could require seizure prophylaxis.
主要研究者姓名:莫拉,Lidia Maria Veras罗查德
项目名称:Medicare计划中癫痫预防的比较安全性
1R01AG073410-01
每年有数千名患有阿尔茨海默病和/或阿尔茨海默病相关痴呆(AD/ADRD)的医疗保险受益人接受抗惊厥药物以预防癫痫发作。考虑到癫痫后遗症的严重程度,这些药物可以挽救生命,但由于严重的不良事件,也会危及生命。AD/ADRD患者特别容易受到卒中和不良事件的影响。当患者患有AD/ADRD时,开始和停止抗惊厥药的决定也可能改变,部分原因是当患者难以接受治疗范围狭窄或难以识别早期并发症症状时,抗惊厥治疗管理变得更加复杂。没有试验数据来指导有或没有AD/ADRD的患者在缺血性卒中后的预防决策。现有文献稀少且相互矛盾,但由于难以评估相关措施,卒中严重程度或AD/ADRD状态。医疗保险索赔提供了潜在的,但缺乏充分验证的定义中风的严重程度,AD/ADRD状态,癫痫发作,或不良反应。我们将使用一个新的数据集来解决这些问题,该数据集包含来自登记处、电子健康记录和医疗保险索赔的个人水平相关纵向信息,并将为关键基线和结果变量开发预测模型。然后,使用18年(2006-23年)全国传统的按服务收费的医疗保险索赔的随机20%样本,我们将模拟临床试验,评估在有或没有AD/ADRD的患者中首次发生轻度至中度缺血性卒中时的两个关键决定:a)开始门诊预防与不开始预防;和B)在6个月时停止预防与继续预防。我们将应用多种分析工具来解决混淆和其他挑战。我们将根据AD/ADRD状态对我们的人群进行分层,因为与无AD/ADRD的患者相比,患者的卒中、卒中后癫痫发作和治疗并发症模式不同,临床管理模式也不同。我们有三个目标:1)验证我们研究变量的基于索赔的预测模型; 2)模拟一项临床试验,比较门诊预防开始与否; 3)模拟一项临床试验,比较在6个月时停止门诊预防与继续门诊预防。这项比较安全性研究可以为未来的政策和临床护理提供信息,并改善卒中和AD/ADRD护理,例如,通过调整医疗保险质量激励措施和临床指南。此外,这些数据可以帮助患者,家庭,临床医生和政策制定者了解我们如何改善对可能需要癫痫预防的患者的护理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lidia Maria Veras Rocha de Moura其他文献
Lidia Maria Veras Rocha de Moura的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lidia Maria Veras Rocha de Moura', 18)}}的其他基金
Traumatic Brain Injury Anti-Seizure Prophylaxis in the Medicare Program
医疗保险计划中的创伤性脑损伤抗癫痫预防
- 批准号:
10715238 - 财政年份:2023
- 资助金额:
$ 82.52万 - 项目类别:
Comparative Safety of Seizure Prophylaxis within the Medicare Program
医疗保险计划中癫痫预防的比较安全性
- 批准号:
10277748 - 财政年份:2021
- 资助金额:
$ 82.52万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 82.52万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 82.52万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 82.52万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 82.52万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 82.52万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 82.52万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 82.52万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 82.52万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 82.52万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 82.52万 - 项目类别:
Operating Grants